IRVINE, Calif., May 24, 2006 (PRIMEZONE) -- "As expected, a group of public companies are moving forward in their research and development of drug eluting coated stents. Stents are expandable wire-mesh devices placed in clogged blood vessels to prop open the vessels to maintain healthy blood flow to the heart or elsewhere in the body," stated SmallCap Sentinel analyst D.R. Clark.
A publication of results of a research study in one of the nation's most respected medical journals, which examined the performance of drug-coated stents in cardiovascular disease patients, recently reported in the Journal of the American Medical Association (JAMA), confirmed findings of prior research indicating that commonly used drug-coated stents cause a much higher rate of complications and death than previously thought. The report further validates the importance of research by stent technology companies toward creation of improved technology, in particular the need for stents that demonstrate improved biocompatibility.
"This illustrates the need for further innovation and research in the stent arena and opens the competitive door for companies like MIV Therapeutics (OTCBB:MIVT), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices," Clark added.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address stents and stent related companies including MIV Therapeutics, Inc. (OTCBB:MIVT), Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Boston Scientific (NYSE:BSX). The report will place specific emphasis on drug eluting stents, their design, application, and imperative need.
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Individuals may also register to receive free future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.